Posted by Michael Wonder on 29 Jun 2022
ObsEva announces UK MHRA marketing authorisation for Yselty (linzagolix), an oral GnRH antagonist, for the treatment of uterine fibroids
28 June 2022 - Theramex to commercialise Yselty; ObsEva to receive royalties on commercial sales, as well as development, commercial, and sales based milestone payments.
ObsEva today announced that the UK MHRA has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids in adult women (over 18 years of age) of reproductive age.
